Aitia’s Gemini Digital Twin (GDT) platform merges our proprietary causal AI reverse-engineering forward-simulation (REFS) engine with unprecedented supercomputing power and massive human patient multiomic and clinical data to develop in silico models of human disease biology that inform drug discovery and development at every step of the biopharma pipeline.
Our Gemini Digital Twin platform reveals the molecular interactions that cause diseases and identifies a set of novel potential intervention points. These findings can be used by our biopharma partners to discover, develop, and throughly test (at the bench and in the clinic) newly discovered and precisely targeted drugs.
Aitia’s causal AI-based Gemini Digital Twin platform fuels differentiated and novel partnered programs across multiple diseases with high unmet medical need.
We are a world-class team of AI pioneers, R&D veterans, and biotech company builders backed by top-tier healthcare and strategic pharma investors and leaders working together toward our mission.
Our technology, data, and expertise in generating deep biological knowledge dovetails perfectly with our partner’s own data and pharmaceutical R&D expertise to accelerate the discovery and development of new therapies for multiple areas of unmet medical need, e.g., oncological, neuro-degenerative, immunological, and cardiometabolic diseases.
